Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today ...

Saxenda (liraglutide) is a GLP-1 agonist injection pen medication used to support long-term weight loss in adults with obesity, adults with overweight and weight-related health issues, and certain ...

If you are overweight or obese, you might be advised to lose weight by your GP, especially if it is causing you related health problems. You may also wish to lose weight for your own personal reasons.

Saxenda Approved for Weight Management The FDA has approved Saxenda (liraglutide [rDNA origin]) injection for chronic weight management. Saxenda is the first glucagon-like peptide-1 (GLP-1) receptor ...

These findings further confirm the safety profile of Saxenda and are comparable to the safety data seen at 56 weeks. Novo Nordisk announced that the Food and Drug Administration (FDA) has approved a ...

Novo Nordisk A/S (NVO) announced that the FDA has approved an updated label for Saxenda (liraglutide) injection 3 mg. The Saxenda Injection is now approved for the treatment of obesity in adolescents ...

Novo Nordisk announced the launch of Saxenda (liraglutide [rDNA origin]) injection as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult ...

In a world full of chocolate biscuits and crisps, losing weight is a tough task for most — however hope could be around the corner for those who can't quite kick the snack cupboard yet. High street ...

Boots and other online pharmacies are offering a weight-loss injection for people with a BMI over 30. Saxenda, which is available from Boots for £150 for three pens, is described as a 'weight loss ...